Genes influence GLP-1 weight-loss drug responses and side effects

Genetic differences, including a GLP1R variant and a GIPR variant, modestly affect how much weight people lose and their risk of nausea on GLP-1 obesity drugs; the weight-loss difference is small—about 1.7 lb more at eight months for one copy and ~3.3 lb for two copies. A GIPR variant was linked to higher nausea with tirzepatide. Separately, higher GLP-1 doses may confer cardiovascular benefits that seem independent of weight loss, suggesting dosing could optimize heart outcomes; tissue data indicate potential direct cardiac effects, warranting further study.